Publications

Natural compounds such as polyphenols, flavonoids, alkaloids, terpenoids, and saponins demonstrate significant anti-obesity potential by regulating adipogenesis, lipolysis, appetite, and energy expenditure. However, their clinical application is limited by poor solubility, low bioavailability, rapid metabolism, and instability in the gastrointestinal tract. Nanoformulation strategies including polymeric nanoparticles, lipid-based carriers, micelles, dendrimers, and nanoemulsions offer promising solutions to these barriers. By improving solubility, protecting bioactives from degradation, enhancing absorption, and enabling targeted or sustained release, nanoformulations significantly enhance therapeutic efficacy. This review explores the principles of nanoformulation, preclinical and clinical advances, translational barriers, clinical perspectives, and future directions for integrating nanotechnology with natural product–based obesity therapy. Nanoformulations may transform natural bioactives into clinically viable anti-obesity treatments, though long-term safety, cost, and regulatory concerns remain critical challenges. Keywords: Nanoformulations, Natural compounds, Obesity, Nanocarriers, Bioavailability